Sysmex Inostics, Bayer to Develop Companion Diagnostics for Cancer Therapies | GenomeWeb

NEW YORK (GenomeWeb News) — Sysmex Inostics said today that it has inked a collaboration agreement with Bayer Healthcare to develop blood-based companion diagnostics for targeted anti-cancer therapies being developed by Bayer.

Under the agreement, Sysmex Inostics, a subsidiary of Japanese in vitro diagnostics firm Sysmex, will develop blood-based diagnostic tests using its BEAMing technology, an ultra-sensitive digital PCR approach that can detect cancer cell DNA directly from blood.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.